Generali Asset Management SPA SGR Sells 93,749 Shares of Pfizer Inc. $PFE

Generali Asset Management SPA SGR lessened its stake in Pfizer Inc. (NYSE:PFE) by 31.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 208,990 shares of the biopharmaceutical company’s stock after selling 93,749 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Pfizer were worth $5,325,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Pfizer during the 2nd quarter worth approximately $2,270,157,000. Vanguard Group Inc. raised its position in Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Pfizer by 43.4% during the second quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock worth $453,747,000 after purchasing an additional 5,662,309 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Pfizer by 75.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock valued at $221,398,000 after purchasing an additional 3,722,531 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Pfizer by 84.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock valued at $183,302,000 after purchasing an additional 3,472,240 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Up 1.1%

Shares of NYSE PFE opened at $25.17 on Friday. The company has a 50 day simple moving average of $25.18 and a 200 day simple moving average of $24.90. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a market cap of $143.13 billion, a PE ratio of 14.64 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on PFE shares. Morgan Stanley dropped their price objective on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Citigroup started coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price objective for the company. Finally, The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.06.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: BMO Capital reaffirmed an Outperform rating and a $30 price target, citing Pfizer’s cost controls and a cautious-but-manageable 2026 outlook — a clear vote of confidence for investors focused on valuation and income. BMO reaffirmation
• Positive Sentiment: Multiple bullish analyst/publication pieces argue Pfizer is undervalued and that its pipeline plus deal-making (Seagen, recent obesity-related buys) position it to recover over time — supporting a value-oriented rally. See Fool’s take on medium-term upside. 2 Predictions for Pfizer in 2026
• Positive Sentiment: Analysts at Zacks raised certain near-term quarterly EPS estimates (Q2 2026/Q2 2027), which can help sentiment around upcoming reports and show some upside to consensus in select periods.
• Neutral Sentiment: In-depth pieces (Seeking Alpha, Yahoo Finance) frame 2026 as a “reset” year: higher R&D and acquisition-driven repositioning (notably the Metsera deal) should strengthen Pfizer’s obesity and oncology lineup, but benefits may take time to show. Pfizer 2026: The Reset Year Why Wall Street Gave Up on Pfizer
• Neutral Sentiment: Market commentary reiterates Pfizer’s cheap forward valuation versus peers and highlights that recent M&A (Seagen, Metsera) is beginning to add revenue and late‑stage assets — a longer‑term positive but not immediate earnings relief.
• Negative Sentiment: Pfizer disclosed a death in a long‑term Hympavzi study after a thrombotic stroke — a safety event that could weigh on that program’s outlook and near‑term sentiment. Hympavzi study death
• Negative Sentiment: Analyst estimate trims and management comments point to earnings pressure from the post‑COVID revenue decline and dilution from acquisitions; Zacks trimmed a Q4 EPS estimate — reinforcing near‑term earnings uncertainty.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.